NCT00485979 - Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients | Biotech Hunter

Enrollment

330

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions

Breast Neoplasms

Interventions

DRUG

larotaxel (XRP9881)

intravenous administration

DRUG

docetaxel

intravenous administration

DRUG

trastuzumab

intravenous administration

Trial Locations (8)

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Mégrine

Sanofi-Aventis Administrative Office, Guildford

Sanofi-Aventis Administrative Office, Montevideo